Who are low-dose ticagrelor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aspirin and clopidogrel / Prasugrel, aspirin and/or clopidogrel, Chewing Ticagrelor LD, OAC + clopicogrel, bivalirudin + clopidogrel + aspirin, ASA plus Clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-ticagrelor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

low-dose ticagrelor — Competitive Intelligence Brief

low-dose ticagrelor (low-dose ticagrelor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist. Area: Cardiovascular.

marketed P2Y12 receptor antagonist P2Y12 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

low-dose ticagrelor (low-dose ticagrelor) — First Affiliated Hospital of Harbin Medical University. Low-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
low-dose ticagrelor TARGET	low-dose ticagrelor	First Affiliated Hospital of Harbin Medical University	marketed	P2Y12 receptor antagonist	P2Y12
Aspirin and clopidogrel / Prasugrel	Aspirin and clopidogrel / Prasugrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy combination)	COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel)
aspirin and/or clopidogrel	aspirin and/or clopidogrel	Asan Medical Center	marketed	Antiplatelet agent	COX (aspirin); P2Y12 receptor (clopidogrel)
Chewing Ticagrelor LD	Chewing Ticagrelor LD	Sheba Medical Center	marketed	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist class)

First Affiliated Hospital of Harbin Medical University · 4 drugs in this class
Fu Wai Hospital, Beijing, China · 1 drug in this class
Ping-Yen Liu · 1 drug in this class
Samsung Medical Center · 1 drug in this class
St. Antonius Hospital · 1 drug in this class
University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low-dose ticagrelor — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-ticagrelor. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab